QDEL Stock — QuidelOrtho Corporation

QuidelOrtho Corporation (QDEL)

Updated October 16, 2026.

QDEL is a Stock. Total return is 143.0% over the past 35.7 years.

QuidelOrtho Corporation provides diagnostic testing solutions across clinical chemistry, immunoassay, transfusion medicine, point-of-care, and molecular diagnostics through instruments and tests sold globally to hospitals, laboratories, physician offices, blood banks, and other healthcare settings. The company does not currently have an established distribution program. This equity security may appeal to investors seeking exposure to the healthcare diagnostics sector without reliance on dividend income.

QDEL performance

Price and return data through 2026-10-16.

Total return is 143.0% over the past 35.7 years. Over the past year its total return — price change plus distributions reinvested — is -54.6%. Its deepest 1-year drawdown was 71.8%.

QDEL key facts

Asset type

Stock

Asset class

Equity

Inception date

02/01/1991

Distribution frequency

None

Last close

$12.91 (as of 2026-10-16)

Market cap

$885,308,763

Average volume

1787830.0

Beta

0.783

Payout ratio

0.0%

Forward P/E

9.5877

EPS

$-16.64

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

QDEL risks and drawbacks

The deepest 1-year drawdown on record here is 71.8%.

Who may consider QDEL — and who may not

It is a weaker fit for investors who need monthly cash flow (QDEL does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on QDEL

• All tickers starting with Q

Tagged: Healthcare.

Frequently asked questions